

DEPARTMENT OF HEALTH AND HUMAN SERVICES

HT-36

Public Health Service

Food and Drug Administration New Orleans District Office 6600 Plaza Drive, Suite 400 New Orleans, LA 70127

November 29, 2000

VIA FEDERAL EXPRESS

FACILITY ID# 193615

Tom McDougal, C.E.O. L.V. Stabler Hospital 29 L.V. Stabler Drive Greenville, AL 36037 Jurga 14/12/10 850

Warning Letter No. 01-NSV-07

Dear Mr. McDougal:

Your facility was inspected on November 7, 2000 by a representative of the State of Alabama on contract to the Food and Drug Administration (FDA). This inspection revealed that your facility failed to comply with the Quality Standards for Mammography (Standards) as specified in Title 21, <u>Code of Federal Regulations</u> (CFR), Part 900.12, as follows:

Level 2 (Repeat finding)

of random reports reviewed did not contain an assessment category for site L.V. Stabler Hospital.

The previous inspection of September 17, 1999 also found for an assessment category for site L.V. Stabler Hospital. Your response of November 8, 1999 indicated that this deficiency had been corrected.

This deficiency noted during the November 7, 2000 inspection appeared on the Post Inspection Report which was sent to your facility by the state inspector along with instructions on how to respond to these findings. This deficiency may be symptomatic of serious problems that could compromise the quality of mammography at your facility and potentially overexpose both patients and employees involved with mammography.

It is your responsibility to ensure adherence to each requirement of the Mammography Quality Standards Act of 1992 (MQSA) and FDA's regulations. You are responsible for investigating and determining the cause of these deficiencies as identified and to promptly initiate permanent corrective action.

If you fail to properly address this deficiency, FDA may, without further notice, initiate regulatory action. Under MQSA, FDA may:

• impose civil money penalties on a facility of up to \$10,000 for each failure to substantially comply with, or each day of failure to comply with the Standards.

Warning Letter No. 01-NSV-07 L.V. Stabler Hospital

- suspend or revoke a facility's FDA certificate for failure to comply with the Standards
- seek an injunction in federal court to prohibit any mammography activity that constitutes a serious risk to human health.

Within 15 working days after receiving this letter, you should notify FDA in writing of each step your facility is taking to prevent the recurrence of any similar violation.

If your facility is unable to complete this corrective action within 15 working days, you should state the reason for the delay and the time within which the correction will be completed.

Your reply should be directed to Joseph E. Hayes, Compliance Officer, Food and Drug Administration, 297 Plus Park Boulevard, Nashville, Tennessee 37217, telephone 615/781-5389, extension 125, with a copy to the State of Alabama. Any questions in regard to this letter or how to ensure you are meeting MQSA standards, please call Karen Smallwood, Radiation Specialist, at 615/781-5380, extension 144.

Sincerely,

Carl & Crayer
Carl E. Draper

Director, New Orleans District

CED:KRS:man

cc: Richard Glass
Alabama Dept. of Public Health
Office of Radiation Control
201 Monroe Street, Suite 700
P.O. Box 303017
Montgomery, AL 36104

Priscilla F. Butler, M.S.
Director, Breast Imaging Accreditation Programs
Standards and Accreditation Department
American College of Radiology
1891 Preston White Drive
Reston, Virginia 20191